While one cell line model has indicated a role for RET expression alone in the endocrine-resistant phenotype, the bulk of the findings above indicate that primary tumor expression of the GFL family ligands is the critical factor governing RET-mediated therapeutic resistance. Here, RET is linked to neoplasm.